Assessing developability early in the discovery process for novel biologics

Assessing developability early in the discovery process for novel biologics

ABSTRACTBeyond potency, a good developability profile is a key attribute of a biological drug. Selecting and screening for such attributes early in the drug development process can save resources and avoid costly late-stage failures. Here, we review some of the most important developability properti...

Täydet tiedot

Bibliografiset tiedot
Päätekijät: Monica L. Fernández-Quintero, Anne Ljungars, Franz Waibl, Victor Greiff, Jan Terje Andersen, Torleif T. Gjølberg, Timothy P. Jenkins, Bjørn Gunnar Voldborg, Lise Marie Grav, Sandeep Kumar, Guy Georges, Hubert Kettenberger, Klaus R. Liedl, Peter M. Tessier, John McCafferty, Andreas H. Laustsen
Aineistotyyppi: Artikkeli
Kieli:English
Julkaistu: Taylor & Francis Group 2023-12-01
Sarja:mAbs
Aiheet:
Biologics
developability
antibodies
drug development
biotherapeutics
drug discovery
Linkit:https://www.tandfonline.com/doi/10.1080/19420862.2023.2171248

Internet

https://www.tandfonline.com/doi/10.1080/19420862.2023.2171248

Samankaltaisia teoksia